WuXi Biology has significant experience in oncology drug discovery. We offer a large collection of tumors models for small and large molecule drug development, including:

• Cell line-derived xenograft (CDX) tumor models
• Patient-derived xenograft (PDX) tumor models
• Syngeneic tumor models
• Human immune checkpoint gene KI mouse models
• hPBMC/HSC humanized models

• 320+ validated models, covering 30 cancer types
• 77+ cell lines derived from PDX models
• Imaging-based orthotopic/metastatic tumor models
• Brain/bone metastatic models of lung/breast cancer cell lines
• Validated models for efficacy testing of antibody-drug conjugates (ADCs)
• Extensive panel of c-MET related CDX models

• Covering 17 tumor types
• Bioluminescent imaging system
• Specific-pathogen-free (SPF) barrier

• 1,400+ PDX models covering full range of cancer types
• Fully-characterized models with genetic, molecular and pharmacological profiling
• Drug-resistant PDX models available
• in vitro screening and derivative PDXC/PDXO models
• Validated models for efficacy testing of antibody-drug conjugates (ADCs)
• Extensive panel of c-MET related PDX models
• PDX panel with hPBMC humanization
• Tailored platform of PDX models based on the classification of BRAF mutations

• 87 syngeneic models (mouse, rat, hamster)
• Comprehensive panel of orthotopic syngeneic tumor models
• Responsiveness to immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4)
• Tumor-infiltrating leukocytes (TILs) map
• WES, RNA-seq and scRNA-seq characterization

hPBMC Humanized Models

• Established models for immune-checkpoint inhibitor and bi-specific antibody candidates in a human-resembling immune system.
• Annotation for both immune cells (phenotyping, biomarker, functions) and tumor cells (expression, mutation)
• Different PBMC delivery systems (systemic injection or co-inoculation with tumor)

HSC Humanized Models

• Available humanized models from CIEA combined with WuXi PDX/CDX models.
• Customizable with human cytokine transgenic mice (GM-CSF/hIL-3 or hIL-2) to improve the reconstitution of myeloid lineage.

KI (Knock-in) mice offer the possibility to study checkpoint antibodies targeting human checkpoints in the context of a fully functional immune system.

• Collection of various targets and background mouse strains
• Validated with launched or most advanced clinical grade checkpoint antibodies
• Double checkpoint KI mice customizable for combination (PD1 + OX40, PD1 + TIM3)